Adis celebrates significant gains in 2013 Impact Factor announcement

Adis, a leading publisher of drug-focused medical journals, is celebrating after the 2013 Journal Citation Reports® revealed substantial growth in Impact Factors for a number of its titles.

The most outstanding success was that of Molecular Diagnosis & Therapy, which saw its Impact Factor increase 53% over the year, taking it to 2.589. The journal focuses on molecular diagnostic and pharmacogenomics techniques and their application in the fast-moving field of personalized medicine.

md_cvr
Molecular Diagnosis & Therapy

Other noteworthy results include the American Journal of Clinical Dermatology and The Patient: Patient-Centered Outcomes Research, the Impact Factors of which increased by 37% and 25% respectively.

PharmacoEconomics, a title focusing on the cost-effective use of drug therapy for decision makers, maintained its position as the highest ranked health economics and outcomes research journal with a growth of 17%.

At the beginning of 2014, Adis expanded its journal portfolio to incorporate eleven Adis Rapid+ Journals, formerly known as Springer Healthcare Rapid Publications. The flagship title from this portfolio, Advances in Therapy, has continued to build on previous years’ successes with a further improved Impact Factor of 2.438. Adis also added two Springer journals to its offerings, European Journal of Drug Metabolism and Pharmacokinetics and Targeted Oncology, both of which saw double digit increases in the latest announcement.

The Journal Citation Reports® from Thomson Reuters are a measure of a journal’s impact, representing the number of times an article from each title is cited on average.

Adis has a portfolio of over 30 medical journals and newsletters, offering reputable and independent content of interest to anyone involved in medical research, practice or teaching; drug regulation or reimbursement; or those in the pharmaceutical industry.